TCM
KDNY

Tekla Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Tekla Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$5.8M Buy
150,863
+67,363
+81% +$1.73M 0.23% 81
2023
Q1 		$1.93M Buy
+83,500
New +$1.99M 0.07% 121

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tekla Capital Management's KDNY Position: Q2 2023 in Review

Tekla Capital Management increased its Chinook Therapeutics, Inc. Common Stock (KDNY) stake by 81% in Q2 2023, buying an estimated $1.73M and bringing the position to 150,863 shares worth $5.8M. The position accounts for 0.23% of the portfolio, ranked #81.

Tekla Capital Management first reported a position in KDNY in Q1 2023 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Tekla Capital Management held 150,863 shares of Chinook Therapeutics, Inc. Common Stock worth $5.8M as of Q2 2023.
  • Tekla Capital Management bought 67,363 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.73M.
  • Chinook Therapeutics, Inc. Common Stock made up 0.23% of Tekla Capital Management's portfolio in Q2 2023, its #81 holding.
  • Tekla Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2023 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.